Status:
RECRUITING
Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer
Lead Sponsor:
Jinming Yu
Conditions:
Non-small Cell Lung Cancer (NSCLC)
Eligibility:
All Genders
18+ years
Brief Summary
This study is a national multicenter real-world investigation aimed at evaluating the real-world effectiveness and safety of Iruplinalkib in the treatment of ALK-positive NSCLC in China. The study ai...
Eligibility Criteria
Inclusion
- Patients willingly contribute their clinical data for this study
- Patients with ALK-positive non-small cell lung cancer
- Age ≥ 18 years
- Patients who have undergone treatment with Iruplinalkib.
Exclusion
- Known pregnant or lactating females
- Patients with interstitial lung diseases, drug-related pneumonitis, or radiation pneumonitis require ongoing medical intervention.
Key Trial Info
Start Date :
July 24 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT05991895
Start Date
July 24 2023
End Date
July 1 2026
Last Update
August 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shandong Cancer Hospital and Institute
Jinan, Shandong, China